2026-04-17T13:55:09Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4841872025-08-31T18:11:07Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Sancho-Saldaña, Agustín author Gil Sánchez, Anna author González-Mingot, Cristina author Peralta, Silvia author Solana, Maria Jose author Torres, Pascual author Juanes, Alba author Quibus, Laura author Ruiz, Emilio author Sanpedro, Eduardo author Quirant, Bibiana author Martínez Cáceres, Eva María author Ramo-Tello, Cristina author Presas Rodríguez, Sílvia author García Rubio, Sebatián author Baron, Beatriz Pardiñas author Ramió-Torrentà, Lluís author Sotoca Fernández, Javier author González-Suárez, Inés author Eichau Madueño, Sara author Prieto, Jose Maria author Blasco Quilez, Maria Rosario author Sabín-Muñoz, Julia author Sánchez-López, Antonio José author Llorens Calatayud, Gloria author Calles, Carmen author Perez-Sempere, Angel author Garces, Moises author Carmona, Olga author Moral, Ester author Hervás, José Vicente author Blanco, Yolanda author Sola-Valls, Nuria author Téllez Lara, Nieves author Forero, Lucía author Brieva Ruiz, Luis author 2023 Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies : A Multi-Centre Study